Using Personalized Immunotherapies to Advance Melanoma Treatment
DOI:
https://doi.org/10.58445/rars.1657Keywords:
Melanoma, skin cancer, ImmunotherapiesAbstract
Melanoma, a fatal type of skin cancer, presents a prominent challenge in oncology due to its high mortality rate and aggressive pathology. This emphasizes the need for new, effective treatments to tackle this disease. Immunotherapy, harnessing a patient’s own immune system to fight off cancer, presents a promising solution. Specifically, personalized immunotherapy offers a precise, targeted approach to combat the complexities of the cancer, tailoring treatments to the unique characteristics of each patient. Given the challenges associated with melanoma treatment, there is a growing interest in harnessing the power of the immune system through personalized immunotherapy to improve patient outcomes. This review explores how utilizing personalized treatments alongside traditional immunotherapy such as immune checkpoint inhibitors, oncolytic viruses, and cell therapy, significantly improves patient outcome.
References
Abdel-Malek, Z. A., Kadekaro, A. L., & Swope, V. B. (2010). Stepping up melanocytes to the challenge of UV exposure. Pigment Cell & Melanoma Research, 23(2), 171–186. https://doi.org/10.1111/j.1755-148X.2010.00679.x
Andtbacka, R. H. I., Curti, B. D., Kaufman, H., Daniels, G. A., Nemunaitis, J. J., Spitler, L. E., Hallmeyer, S., Lutzky, J., Schultz, S. M., Whitman, E. D., Zhou, K., Karpathy, R., Weisberg, J. I., Grose, M., & Shafren, D. (2015). Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. Journal of Clinical Oncology, 33(15_suppl), 9030–9030. https://doi.org/10.1200/jco.2015.33.15_suppl.9030
Bagchi, S., Yuan, R., & Engleman, E. G. (2021). Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16(1), 223–249. https://doi.org/10.1146/annurev-pathol-042020-042741
Bradley, S., Jakes, A., Harrington, K., Pandha, H., Melcher, A., & Errington-Mais, F. (2014). Applications of coxsackievirus A21 in oncology. Oncolytic Virotherapy, 47. https://doi.org/10.2147/OV.S56322
Brady, J., Kashlan, R., Ruterbusch, J., Farshchian, M., & Moossavi, M. (2021). Racial Disparities in Patients with Melanoma: A Multivariate Survival Analysis. Clinical, Cosmetic and Investigational Dermatology, 14, 547–550. https://doi.org/10.2147/CCID.S311694
Chu, Y., Liu, Q., Wei, J., & Liu, B. (2018). Personalized cancer neoantigen vaccines come of age. Theranostics, 8(15), 4238–4246. https://doi.org/10.7150/thno.24387
De Miguel, M., & Calvo, E. (2020). Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell, 38(3), 326–333. https://doi.org/10.1016/j.ccell.2020.07.004
Delhalle, S., Bode, S. F. N., Balling, R., Ollert, M., & He, F. Q. (2018). A roadmap towards personalized immunology. Npj Systems Biology and Applications, 4(1), 1–14. https://doi.org/10.1038/s41540-017-0045-9
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022). Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. International Journal of Molecular Sciences, 23(5), Article 5. https://doi.org/10.3390/ijms23052847
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., Dronca, R., Mitchell, T. C., Patnaik, A., Zarour, H. M., Joshua, A. M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N., & Ribas, A. (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology, 30(4), 582–588. https://doi.org/10.1093/annonc/mdz011
Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015). Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy, 7(6), 611–619. https://doi.org/10.2217/imt.15.35
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015). Pembrolizumab. Journal for ImmunoTherapy of Cancer, 3(1), 36. https://doi.org/10.1186/s40425-015-0078-9
Kuryk, L., Bertinato, L., Staniszewska, M., Pancer, K., Wieczorek, M., Salmaso, S., Caliceti, P., & Garofalo, M. (2020). From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers, 12(10), Article 10. https://doi.org/10.3390/cancers12103057
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017). Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncology, 3(6), 841–849. https://doi.org/10.1001/jamaoncol.2016.2064
Lee, L., Gupta, M., & Sahasranaman, S. (2016). Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. The Journal of Clinical Pharmacology, 56(2), 157–169. https://doi.org/10.1002/jcph.591
Mandal, R., & Chan, T. A. (2016). Personalized Oncology Meets Immunology: The Path Towards Precision Immunotherapy. Cancer Discovery, 6(7), 703–713. https://doi.org/10.1158/2159-8290.CD-16-0146
Mansh, M. (2011). Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma. The Yale Journal of Biology and Medicine, 84(4), 381–389.
Mantwill, K., Klein, F. G., Wang, D., Hindupur, S. V., Ehrenfeld, M., Holm, P. S., & Nawroth, R. (2021). Concepts in Oncolytic Adenovirus Therapy. International Journal of Molecular Sciences, 22(19), Article 19. https://doi.org/10.3390/ijms221910522
Martin-Liberal, J., Kordbacheh, T., & Larkin, J. (2015). Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety, 14(6), 957–964. https://doi.org/10.1517/14740338.2015.1021774
McCart, J. A., Wang, Z.-H., Xu, H., Hu, Y., Park, B., Alexander, H. R., & Bartlett, D. L. (2002). Development of a Melanoma-Specific Adenovirus. Molecular Therapy, 6(4), 471–480. https://doi.org/10.1006/mthe.2002.0692
Merlino, G., Herlyn, M., Fisher, D. E., Bastian, B. C., Flaherty, K. T., Davies, M. A., Wargo, J. A., Curiel-Lewandrowski, C., Weber, M. J., Leachman, S. A., Soengas, M. S., McMahon, M., Harbour, J. W., Swetter, S. M., Aplin, A. E., Atkins, M. B., Bosenberg, M. W., Dummer, R., Gershenwald, J. E., … Ronai, Z. A. (2016). The state of melanoma: Challenges and opportunities. Pigment Cell & Melanoma Research, 29(4), 404–416. https://doi.org/10.1111/pcmr.12475
Paulson, K. G., Gupta, D., Kim, T. S., Veatch, J. R., Byrd, D. R., Bhatia, S., Wojcik, K., Chapuis, A. G., Thompson, J. A., Madeleine, M. M., & Gardner, J. M. (2020). Age-Specific Incidence of Melanoma in the United States. JAMA Dermatology, 156(1), 57–64. https://doi.org/10.1001/jamadermatol.2019.3353
Reynolds, C. R., Tran, S., Jain, M., & Narendran, A. (2022). Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies. Vaccines, 10(2), Article 2. https://doi.org/10.3390/vaccines10020196
Robert, C., Schadendorf, D., Messina, M., Hodi, F. S., O’Day, S., & for the MDX010-20 investigators. (2013). Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control. Clinical Cancer Research, 19(8), 2232–2239. https://doi.org/10.1158/1078-0432.CCR-12-3080
Rogiers, A., Boekhout, A., Schwarze, J. K., Awada, G., Blank, C. U., & Neyns, B. (2019). Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. Journal of Oncology, 2019, e5269062. https://doi.org/10.1155/2019/5269062
Rotte, A., & Bhandaru, M. (2016). Immunotherapy of Melanoma. Springer.
Tarhini, A., & Kudchadkar, R. R. (2018). Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Cancer Treatment Reviews, 71, 8–18. https://doi.org/10.1016/j.ctrv.2018.09.005
Downloads
Posted
Categories
License
Copyright (c) 2024 Shreya Santhosh
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.